BOTHELL, Wash., Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the ...

The world's leading carbon negative materials company November 9, 2023 FORWARD-LOOKING STATEMENTS This presentation contains Origin's projected financial information. Such projected financial information is forward-looking and is for illustrative purposes only. It should not be relied upon as being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to many significant business, economic, competitive and other r ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participants Jacob Johnson - Stephen Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Steven Mah - TD Cowen Thomas Flaten - Lake Street Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst ...

8 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------|-----------------------------------|-----------------------------------|-------|---------------------|---------------------|----------------------------|-------|----------------------------------------|---------------------|---------------|----------------------------| | (In thousands, except share data) | Series A Preferred Stock Shares | Series A Preferred Stock Amount | | Co ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Chad Wiatrowski – TD Cowen Amanda Young – KeyBanc Capital Markets Thomas Flaten – Lake Street Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Second Quarter 2023 Shareholders and Analyst ...

____________________________________________________ BioLife Solutions, Inc. Common Stock BLFS NASDAQ Capital Market FORM 10-Q o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Delaware 94-3076866 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is a large accelerated filer, an acce ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Rice - Chairman & CEO Conference Call Participants Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Chad Wiatrowski - TD Cowen Carl Byrnes - Northland Capital Markets Yuan Zhi - B. Riley Securities Paul Knight - KeyBanc Capital Markets Operator Hello. My name is Mallory, and I will be your conference operator today. At this time, I would l ...

Table of Contents Table of Contents BioLife Solutions, Inc. Unaudited Condensed Consolidated Statements of Cash Flows | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------|-------|--------------------------|-------------|-----------| | (In thousands) | | 2023 | March 31, | 2022 | | Cash flows from operating activities | | | | | | Net loss | $ | (13,714) | $ | (7,421) | | Adjustments to reconcile net loss to net cash used in oper ...

In the course of making our assessment of the effectiveness of internal control over financial reporting as of December 31, 2022, we identified several material weaknesses. Material weaknesses were identified in relation to (i) inappropriately designed entity-level controls impacting the control environment, risk assessment, and monitoring activities to prevent or detect material misstatements to the consolidated financial statements attributed to an insufficient number of qualified resources and inadequate ...

Source: Alliance for Regenerative Medicine 1H 2022 Report Active Trials by Therapy 2022 H1 Phase 1 Phase 2 ● Phase 3 Cell therapies: 46% Gene therapies: 18% 15 Accelerator of CAR-T clinical adoption To meet the current and anticipated demand in regulatory reviews and audits, the FDA is hiring 132 new staff in FY 2023 and an additional 96 in FY 2024-27 Biopreservation Challenges Customer Reimbursement Environment 18 BioLife Solutions Analysts and Investors Day March 23,2023 Cell Processing Storage and Servic ...